Serum levels of CA-50, CA-19.9, CA-125, neuron specific enolase and carcinoembryonic antigen in lung cancer and benign diseases of the lung

1989 ◽  
Vol 43 (8) ◽  
pp. 613-620 ◽  
Author(s):  
G. Berthiot ◽  
F. Marechal ◽  
A. Cattan ◽  
G. Deltour
Keyword(s):  
Lung Cancer ◽  
Carcinoembryonic Antigen ◽  
Neuron Specific Enolase ◽  
Serum Levels ◽  
Ca 125 ◽  
Benign Diseases ◽  
Ca 19.9 ◽  
Ca 50

Tumor Markers in Patients with Chronic Renal Failure

1990 ◽  
Vol 5 (2) ◽  
pp. 85-88 ◽  
Author(s):  
X. Filella ◽  
A. Cases ◽  
R. Molina ◽  
J. Jo ◽  
J.L. Bedini ◽  
...  
Keyword(s):  
Renal Failure ◽  
Chronic Renal Failure ◽  
Tumor Markers ◽  
Specific Antigen ◽  
Neuron Specific Enolase ◽  
Serum Levels ◽  
Carbohydrate Antigen ◽  
Ca 125 ◽  
Renal Metabolism ◽  
Ca 50

In order to evaluate the specificity of tumor markers in chronic renal failure, we have determined serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 19.9 (CA 19.9), carbohydrate antigen 50 (CA 50), alfafetoprotein (AFP), neuron-specific enolase (NSE), prostatic acid phosphatase (PAP), prostatic specific antigen (PSA), squamous cell carcinoma antigen (SCC), carbohydrate antigen 15.3 (CA 15.3) and carbohydrate antigen 125 (CA 125) in 30 patients with cronic renal failure and in 36 hemodialyzed patients without clinical evidence of neoplasia. CEA, CA 50, NSE and SCC frequently show increased serum levels, suggesting a renal metabolism, while others remain, generally, within the normal levels.

Relationship of CA 125 and CA 19.9 with lung carcinoma histological subtype: Preliminary study

1989 ◽  
Vol 4 (4) ◽  
pp. 215-220 ◽  
Author(s):  
R. Molina ◽  
P. Santabarbara ◽  
X. Filella ◽  
P. Mengual ◽  
A.M. Ballesta ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Large Cell Carcinoma ◽  
Distant Metastases ◽  
Large Cell ◽  
Serum Levels ◽  
Primary Treatment ◽  
Undifferentiated Carcinoma ◽  
Ca 125 ◽  
Histological Types ◽  
Ca 19.9

The aim of this work was to study the possible utility of simultaneous determination of CA 125 and CA 19.9 in patients with lung cancer. Serum levels of both markers were studied in 87 patients without metastases (Mo), 72 patients with distant metastases (MT) and 15 cases without clinical evidence of disease after primary treatment (NED). Sitxty-five tumors were epidermoid, 34 were adenocarcinomas, 24 were cell undifferentiated carcinomas and 51 were small-cell carcinomas. Sera from 75 healthy subjects and 20 patients with benign lung disease were used as controls. The cutoff values used were 35 and 37 U/ml for CA 125 and CA 19.9, respectively. CA 125 and CA 19.9 serum levels were within normal limits in all control patients. In NED patients these markers were not elevated, except in one with chronic liver disease who showed elevated CA 19.9 (76 U/ml). Twenty-five percent of Mo lung cancer patients and 40.3% of MT cases had CA 19.9 over 37 U/ml. Abnormally high levels of CA 125 were found in 18.7% and 22.9% of Mo and MT patients, respectively. Sixty percent of patients with large cell undifferentiated carcinoma had elevated CA 125 (mean 176 U/ml) compared to 15.4% of patients with all other histological types of tumors combined (54.3 U/ml, p< 0.01). CA 19.9 serum levels were also more often elevated in patients with large cell undifferentiated carcinomas (50%, 7/14 cases) than in other histological types (30%, 36/120 patients), but the difference was not statistically significant. There were no differences in CA 125 and CA 19.9 serum levels in relation to location of metastatic disease including liver. Although the sensitivity of CA 125 and CA 19.9 in lung cancer is low, they may be useful as serum markers of recurrent disease in the follow-up of patients with large cell carcinoma.

Tumor Markers and Lung Cancer: Correlation between Serum and Bronchial Secretion Levels of Cea, Tpa, Canag Ca-50, Nse and Ferritin

1987 ◽  
Vol 2 (3) ◽  
pp. 151-156 ◽  
Author(s):  
Vincenzo Macchia ◽  
Angela Mariano ◽  
Mariarita Cavalcanti ◽  
Anna Coppa ◽  
Ciriaco Cecere ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Simultaneous Determination ◽  
Neuron Specific Enolase ◽  
Bronchial Secretion ◽  
Lung Malignancy ◽  
Ca 50 ◽  
Oat Cell Carcinoma ◽  
Diagnosis Of Lung Cancer

The levels of carcinoembryonic antigeny (CEA), tissue polypeptide antigeny (TPA), CanAg 50, neuron specific enolase (NSE) and ferritin were determined in bronchial secretion and serum of patients with neoplastic and non-neoplastic lung diseases. Simultaneous determination of two or three markers in the serum and in bronchoalveolar lavage (BAL) may be clinically useful for the diagnosis of lung cancer and even for the type of tumor. The positivity of CEA determined simultaneously in serum and in BAL of patients with lung cancer is higher than 80% whereas in patients with benign lung disease it is lower than 40%. The simultaneous assay of TP A in serum and in BAL showed 100% positivity in patients with oat-cell carcinoma, the frequencies of positivity were similar in patients with non-oat-cell carcinoma. For NSE and CanAg CA-50 patients with oat-cell carinoma showed 100% positivity. Simultaneous assay of ferritin in serum and in BAL gave 85% positivity in patients with oat-cell carcinoma and only 23% in patients with non-oat-cell carcinoma. We conclude that the simultaneous determination of CEA and CanAg CA-50 or NSE in serum and in BAL is a useful aid in the diagnosis of lung malignancy.

Phosphohexose Isomerase and Carcinoembryonic Antigen in the Sera of Patients with Primary Lung Cancer

1988 ◽  
Vol 3 (2) ◽  
pp. 113-122 ◽  
Author(s):  
P. Santabárbara ◽  
R. Molina ◽  
J. Estapé ◽  
A.M. Ballesta
Keyword(s):  
Lung Cancer ◽  
Carcinoembryonic Antigen ◽  
Prognostic Significance ◽  
Primary Lung Cancer ◽  
Large Cell ◽  
Serum Levels ◽  
Small Cell ◽  
Prognostic Impact ◽  
Phosphohexose Isomerase

Phosphohexose isomerase (PHI) and carcinoembryonic antigen (CEA) were measured at the time of diagnosis in 300 patients with lung cancer. Serum levels were high in 75.7% and 53.0% of patients respectively. PHI levels were higher in large cell and small cell carcinomas (p < 0.001). CEA levels were higher in adenocarcinomas (p < 0.001). Metastatic carcinomas showed higher levels on PHI and CEA than localized cases. Survival was significantly longer in patients with normal PHI (p < 0.001) and normal CEA (p < 0.005) than in cases with elevated markers. The prognostic significance of PHI persisted in the different pathological types and stages, whereas CEA only had prognostic impact in non-small cell cases. Serial PHI determinations were useful for follow-up in 82.4% of cases with initial abnormal values and in 55.4% of cases with a normal value. Serial CEA was useful in 41% of cases with initially high value but in less than 15% of those with baseline normal. We conclude that PHI has prognostic significance independently of pathology and stage, whereas CEA was a prognostic indicator only in non-small cell cases; serial PHI determinations were useful more often than CEA for follow-up.

Sign in / Sign up

Export Citation Format

Share Document